Ultra-Sound ablation energy for:
Pulmonary Artery Hypertension (PAH)
TIVUS is an investigational intravascular device designed for Renal Denervation procedures to treat patients suffering from Hypertension. Early clinical studies have shown that TIVUS can reduce blood pressure in patients suffering from uncontrolled Hypertension.
SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced that on January 8th 2024, the
The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its
TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive
TEL AVIV, Israel, June 20, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders,
SoniVie announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System for renal artery denervation for the treatment of resistant hypertension.
SoniVie today announced that it has received FDA approval for its IDE for a pivotal study of the Therapeutic Intra-Vascular Ultrasound (TIVUS) System in patients with pulmonary arterial hypertension (PAH).
There are over 10,000 new PAH cases every year, accounting for a $5 billion drug market. More than 75% of those with PAH are female. We expect the market in the US, EU and Japan to rise to $250-300 million 2027. If TIVUS can work in other subgroups of pulmonary hypertension, such as Group 2, the largest subgroup, the market opportunity is more than $1 billion.
REFERENCES:
